60
Participants
Start Date
August 31, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
Dasatinib + Ketoconazole
Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
H. Lee Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
Md Anderson Cancer Center, Houston
Lee S. Rosen M.D., Santa Monica
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY